Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Gela C. Sia"'
Autor:
Natalia Jun, Lisa M. Dauffenbach, Christopher A. Kerfoot, Gela C. Sia, Eric Olsen, Jianping Zheng
Publikováno v:
Cancer Research. 77:4009-4009
Tumor-associated macrophages play an important role in presenting tumor antigens to T cells and are being investigated for their role in sensitivity to immune checkpoint inhibitors such as PD-1 inhibitors. The M2 macrophage subtype, characterized by
Autor:
Natalia Jun, Christopher A. Kerfoot, Lisa M. Dauffenbach, Jianping Zheng, Eric Olsen, Gela C. Sia
Publikováno v:
Cancer Research. 77:1669-1669
Evaluating the density of immune cell subtypes and their relative spatial positioning in cancers has become an important tool in understanding response to immune checkpoint inhibitors. The purpose of this study was to investigate protein expression o
Autor:
Gela C. Sia, Christopher A. Kerfoot, Jianping Zheng, Eric Olsen, Ryan S. Lim, Sherif K. Girees, Patricia A. Cash, Lisa M. Dauffenbach
Publikováno v:
Cancer Research. 74:899-899
The PI3K and MEK pathways promote tumor cell survival through a variety of downstream signals and are commonly explored in cancer research. Many agents are in clinical development and new evidence suggests that a combination of these inhibitors may b
Autor:
Gela C. Sia, Christopher A. Kerfoot, Jianping Zheng, Sherif K. Girees, Ryan S. Lim, Lisa M. Dauffenbach, Patricia A. Cash, Rana Richeh, Eric Olsen
Publikováno v:
Cancer Research. 74:3745-3745
Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase with elevated expression in most human cancers, most notably in invasive metastasis. FAK is involved in cell adhesion, motility, and apoptosis, and it is a target for oncology ther
Autor:
Gela C. Sia, Christopher A. Kerfoot, Sherif K. Girees, Eric Olsen, Lisa M. Dauffenbach, Patricia A. Cash, Ryan S. Lim, Jianping Zheng
Publikováno v:
Molecular Cancer Therapeutics. 12:A35-A35
The MEK pathway is activated in most cancers. Several chemotherapeutic agents target this pathway through inhibition of MEK, ERK or upstream receptor tyrosine kinases and are in clinical trials to treat patients with solid tumors. The use of chemosen
Autor:
Ryan S. Lim, Gela C. Sia, Sherif K. Girees, Eric Olsen, Jianping Zheng, Christopher A. Kerfoot, Patricia A. Cash, Lisa M. Dauffenbach
Publikováno v:
Cancer Research. 73:3510-3510
The AKT protein family plays an important role in cellular survival by inhibiting apoptotic processes and is one of the major downstream targets of the phosphatidylinositol 3-kinase (PI3K) pathway. Mammalian target of rapamycin (mTOR) is a key kinase